SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lilly Reports Phase 3b Data on Taltz and Zepbound Combination

Phase 3b data showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity.

LLY

Related stories